Last reviewed · How we verify

Imfinzi — Competitive Intelligence Brief

Imfinzi (Imfinzi) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed Programmed cell death 1 ligand 1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Imfinzi (Imfinzi) — University Medical Center Groningen.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Imfinzi TARGET Imfinzi University Medical Center Groningen marketed Programmed cell death 1 ligand 1
Imfinzi durvalumab AstraZeneca marketed Programmed Death Ligand-1 Blocker [EPC] Programmed cell death 1 ligand 1 2017-01-01
Bavencio avelumab Merck KGaA marketed Programmed Death Ligand-1 Blocker [EPC] Programmed cell death 1 ligand 1 2017-01-01
Tecentriq atezolizumab Roche marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Programmed cell death 1 ligand 1 2016-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Imfinzi — Competitive Intelligence Brief. https://druglandscape.com/ci/imfinzi. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: